Emergent BioSolutions (EBS) Cash from Investing Activities (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Cash from Investing Activities of -$2.4 million for Q1 2026, down 104.03% year-over-year from $59.5 million in Q1 2025, and up 38.46% quarter-over-quarter from -$3.9 million in Q4 2025.
Emergent BioSolutions (EBS) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$2.4 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 104.03% year-over-year to -$2.4 million; the TTM figure through Mar 2026 stood at $7.5 million (down 96.16% YoY), while the FY2025 annual figure was $69.4 million, down 44.57% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$2.4 million, up from -$3.9 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $257.7 million in Q2 2023, with the low at -$271.6 million in Q3 2022.
- The 5-year median for Cash from Investing Activities is -$4.6 million (2024), against an average of $1.4 million.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 392.03% in 2022, then soared 902.8% in 2023.
- Emergent BioSolutions' Cash from Investing Activities stood at -$45.4 million in 2022, then jumped by 74.89% to -$11.4 million in 2023, then surged by 350.88% to $28.6 million in 2024, then plunged by 113.64% to -$3.9 million in 2025, then surged by 38.46% to -$2.4 million in 2026.
- Business Quant data shows EBS's Cash from Investing Activities at -$2.4 million in Q1 2026, -$3.9 million in Q4 2025, and -$3.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | -52.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -52.30 Mn |
| Jun 30, 2026 | -52.30 Mn |
| Mar 31, 2026 | -2.40 Mn |
| Mar 31, 2026 | -2.40 Mn |
| Dec 31, 2025 | -3.90 Mn |
| Dec 31, 2025 | -3.90 Mn |
| Sep 30, 2025 | -3.40 Mn |
| Sep 30, 2025 | -3.40 Mn |
| Jun 30, 2025 | 17.20 Mn |
| Jun 30, 2025 | 17.20 Mn |
| Mar 31, 2025 | 59.50 Mn |
| Mar 31, 2025 | 59.50 Mn |
| Dec 31, 2024 | 28.60 Mn |
| Dec 31, 2024 | 28.60 Mn |
| Sep 30, 2024 | 112.00 Mn |
| Sep 30, 2024 | 112.00 Mn |
| Jun 30, 2024 | -4.60 Mn |
| Jun 30, 2024 | -4.60 Mn |
| Mar 31, 2024 | -10.80 Mn |
| Mar 31, 2024 | -10.80 Mn |